Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643964 | 0.91 | KCNH2 (0.39) | CYP19A1KIF11KCNH2CYP11B1CYP11B2 | |
| SCHEMBL645491 | 0.91 | KCNH2 (0.38) | ACHEBCHEKCNH2MEN1KMT2A | |
| SCHEMBL645836 | 0.91 | MAOB (0.38) | CYP19A1HTR1AHTR7HTR6ACHE | |
| SCHEMBL644102 | 0.90 | CYP19A1 (0.43) | CYP19A1HTR1AHTR7HTR6ACHE | |
| SCHEMBL647711 | 0.90 | KIF11 (0.47) | CYP19A1HTR1AHTR7HTR6KIF11 | |
| SCHEMBL646931 | 0.90 | KIF11 (0.39) | CYP19A1ACHEBCHEKIF11KCNH2 | |
| SCHEMBL644716 | 0.88 | KIF11 (0.37) | CYP19A1ACHEKIF11KCNH2NPSR1 | |
| SCHEMBL644184 | 0.87 | CYP1A2 (0.45) | CYP19A1HTR1AHTR7HTR6KCNH2 | |
| SCHEMBL644775 | 0.83 | KCNH2 (0.39) | CYP19A1ACHEKIF11KCNH2ALDH1A1 | |
| SCHEMBL644181 | 0.83 | KCNH2 (0.43) | CYP19A1KIF11KCNH2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | CYTOKINETICS, INC. | 2009-09-03 | — | — | US | claimed |
| EP-1956908-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | Cytokinetics, Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007067752-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | CYTOKINETICS, INC. (US) | 2007-06-14 | — | — | WO | claimed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119678-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7919524-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1511734-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2010-06-23 | — | — | EP | disclosed |
| US-7629477-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | CYTOKINETICS, INC. | 2009-09-03 | — | — | US | disclosed |
| US-7491746-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1956908-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | Cytokinetics, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007067752-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | CYTOKINETICS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6924376-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | CYP19A1 996/4885HTR1A 4418/4885HTR7 4451/4885 |
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | TOP2A, TOP2B, TOP1 | CYP19A1 1866/4885HTR1A 4028/4885HTR7 3507/4885 |
| US-20040082638-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | CYP19A1 857/4885HTR1A 4706/4885HTR7 4302/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | CYP19A1 857/4885HTR1A 4706/4885HTR7 4302/4885 |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | CYP19A1 857/4885HTR1A 4706/4885HTR7 4302/4885 |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | CYP19A1 857/4885HTR1A 4706/4885HTR7 4302/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | CYP19A1 857/4885HTR1A 4706/4885HTR7 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.